论文部分内容阅读
一项临床前研究表明 ,血管活性肠肽 (ＶＩＰ)可能会减少一些可引起风湿性关节炎 (ＲＡ)的致残性关节疾病的发生。西班牙的主要研究者Ｄｅｌｇａｄｏ认为 ,ＶＩＰ对ＲＡ及其他慢性炎症疾病和依赖于Ｔｈ1的自身免疫性疾病如节段性回肠炎、多发硬化症和自身免疫性糖尿病可能有潜在
A preclinical study showed that vasoactive intestinal peptide (VIP) may reduce some of the disabling joint disease that can cause rheumatoid arthritis (RA). Delgado, principal investigator of Spain, believes that VIP may have potential for RA and other chronic and Th1-dependent autoimmune diseases such as Crohn’s disease, multiple sclerosis and autoimmune diabetes